Abstract:Abstract Background ROS1 -rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1 -rearranged lung cancers are not yet well-elucidated. Our retrospective study aimed to compare the efficacy of chemotherapy and crizotinib in the first-line treatment of ROS1 -rearranged advanced lung cancer and evaluate various clinical and molecular factors that might impact crizotinib efficacy in real-world practice. Methods Treatment responses, survival outcomes, and patterns of disease progression were analyzed for 235 patients with locally advanced to advanced disease who received first-line chemotherapy ( n = 67) or crizotinib ( n = 168). Results The overall response rate was 85.7% (144/168) for first-line crizotinib and 41.8% (28/67) for chemotherapy. Patients treated with first-line crizotinib ( n = 168) had significantly longer median progression-free survival (PFS) than chemotherapy ( n = 67) (18.0 months vs. 7.0 months, p < 0.001). Patients harboring single CD74-ROS1 ( n = 90) had significantly shorter median PFS with crizotinib than those harboring non- CD74 ROS1 fusions ( n = 69) (17.0 months vs. 21.0 months; p = 0.008). Patients with baseline brain metastasis ( n = 45) had a significantly shorter PFS on first-line crizotinib than those without brain metastasis ( n = 123) (16.0 months vs. 22.0 months; p = 0.03). At progression, intracranial-only progression ( n = 40), with or without baseline CNS metastasis, was associated with longer median PFS than those with extracranial-only progression ( n = 64) (19.0 months vs. 13.0 months, p < 0.001). TP53 mutations were the most common concomitant mutation, detected in 13.1% (7/54) of patients with CD74-ROS1 fusions, and 18.8% (6/32) with non- CD74 ROS1 fusions . Patients with concomitant TP53 mutations (n=13) had significantly shorter PFS than those who had wild-type TP53 ( n = 81) (6.5 months vs. 21.0 months; p < 0.001). PFS was significantly shorter for the patients who harbored concomitant driver mutations ( n = 9) (11.0 months vs 24.0 months; p = 0.0167) or concomitant tumor suppressor genes (i.e., TP53 , RB1 , or PTEN ) ( n = 25) (9.5 months vs 24.0 months; p < 0.001) as compared to patients without concomitant mutations ( n = 58). Conclusion Our results demonstrate that baseline brain metastatic status and various molecular factors could contribute to distinct clinical outcomes from first-line crizotinib therapy of patients with ROS1 -rearranged lung cancer. Clinical trials registration CORE, NCT03646994

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Final Overall Survival, Safety, and Quality of Life Results from a Phase 2 Study of Crizotinib in East Asian Patients with ROS1-Positive Advanced NSCLC

O3-4-1Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC)

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib Versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Phase 3 Study of First-Line Crizotinib Vs Pemetrexed−cisplatin/carboplatin (PCC) in East Asian Patients (pts) with ALK+ Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

[Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC].

P2.14-09 Concurrent TP53 Mutation Adversely Impact the Efficacy of Crizotinib in ROS1-Rearranged Lung Cancer Patients

Efficacy and safety of crizotinib in the treatment of advanced non-small cell Lung cancer with ROS1 gene fusion: A systematic literature review and Meta-Analysis of real-world evidence

P1.01-95 Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement——A Single Chinese Cancer Institute Experience

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice

Crizotinib Vs Platinum-Based Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with Different ROS1 Fusion Variants

P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy: Topic: ALK Clinical

Ros1 Rearrangements Define A Unique Molecular Class of Lung Cancers

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study

Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib

Exceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer